FT Options’s Acadia Pharmaceuticals ACAD Stock Holding History

FT Options’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-62,900	Closed	-$5K	–	343
2016 Q1	$5K	Buy	+62,900	New	+$1.37M	0.01%	266

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FT Options's ACAD Position: Q2 2016 in Review

FT Options sold out of Acadia Pharmaceuticals (ACAD) in Q2 2016, closing a stake of 108 shares — an estimated $3.61K sold.

FT Options first reported a position in ACAD in Q1 2016 and held it in 1 quarter. The position peaked at $3K in Q1 2016. 227 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

FT Options reported no remaining Acadia Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
FT Options sold 108 Acadia Pharmaceuticals shares in Q2 2016, an estimated $3.61K.
FT Options first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 1 quarter.
FT Options's Acadia Pharmaceuticals position peaked at $3K in Q1 2016.
227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.